Cargando…
Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial
BACKGROUND: The ability to quantify an immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential. This study assessed the clinical utility of the quantitative Roche Elecsys(®) Anti-SARS-CoV-2 S assay (ACOV2S) using samples from the 2019-nCoV...
Autores principales: | Jochum, Simon, Kirste, Imke, Hortsch, Sayuri, Grunert, Veit Peter, Legault, Holly, Eichenlaub, Udo, Kashlan, Basel, Pajon, Rolando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807632/ https://www.ncbi.nlm.nih.gov/pubmed/35126362 http://dx.doi.org/10.3389/fimmu.2021.798117 |
Ejemplares similares
-
Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial
por: Jochum, Simon, et al.
Publicado: (2021) -
Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19
por: Kirste, Imke, et al.
Publicado: (2022) -
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
por: Choi, Angela, et al.
Publicado: (2021) -
Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018) -
Design and performance characteristics of the Elecsys anti-SARS-CoV-2 S assay
por: Taffertshofer, Karin, et al.
Publicado: (2022)